Amplia Therapeutics (ASX:ATX) reports five complete responses and improved survival in ACCENT pancreatic cancer trial

Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), a Melbourne-based clinical-stage pharmaceutical company focused on focal adhesion kinase inhibitors, has reported materially upgraded efficacy data from its ACCENT Phase 1b/2a trial, in which narmafotinib is combined with standard gemcitabine and Abraxane chemotherapy in first-line advanced pancreatic cancer patients. An independent central reading of clinical response data, conducted using the internationally standardised RECIST 1.1 criteria, has identified four additional confirmed complete responses, bringing the total to five and establishing a complete response rate of 7.8% across 64 patients, a figure the company describes as unprecedented in this indication. A median overall survival of 11.1 months has also been confirmed from the independent analysis, approximately two months ahead of outcomes recorded in the pivotal MPACT trial that established gemcitabine-Abraxane as the current standard of care. Amplia Therapeutics has been selected to present the full ACCENT dataset at the American Association of Cancer Research annual meeting in San Diego in April 2026, a conference that functions as a primary staging ground for Phase 2 data that can attract partnership or licensing interest from larger oncology developers.

Why is a 7.8% complete response rate in advanced pancreatic cancer considered clinically unprecedented?

Complete responses in first-line advanced pancreatic cancer are extraordinarily rare. The MPACT trial, which enrolled 431 patients and defined the modern chemotherapy benchmark, recorded a complete response rate of just 0.2%. The more recent NAPOLI 3 study, evaluating the NALIRIFOX regimen in 387 patients, produced a CR rate of 0.3%. Against these reference points, the 7.8% CR rate in ACCENT, derived from 64 patients, is a statistically and clinically significant departure from what has historically been achievable in this disease setting. Complete responses are particularly important in pancreatic cancer because they imply full radiological clearance of measurable tumours and metastases for at least two months, without new lesion development. In a cancer characterised by rapid progression and a five-year survival rate below 12%, any signal that a subpopulation of patients is achieving durable tumour disappearance carries serious implications for how the drug is eventually positioned commercially and regulatorily.

The independent central read also identified an additional confirmed partial response beyond what site investigators had previously recorded, lifting the overall objective response rate to 35.9%. This compares to 23% in MPACT and 36.2% in NAPOLI 3. The ORR figure for ACCENT is now essentially equivalent to NAPOLI 3, a trial that underpinned US Food and Drug Administration approval for its combination chemotherapy regimen, NALIRIFOX. That comparison is unlikely to be lost on regulatory strategists at Amplia Therapeutics, as it establishes a credible efficacy baseline for any future application seeking accelerated or conditional approval pathways. Four patients remain on study as of mid-March 2026, with one approaching the two-year mark on trial.

How does narmafotinib’s overall survival data compare to approved pancreatic cancer treatment regimens?

The median overall survival figure of 11.1 months from ACCENT is the data point that carries the most immediate regulatory weight. The MPACT trial, which established gemcitabine-Abraxane as the standard of care, recorded a median OS of 8.5 months. NAPOLI 3, which evaluated NALIRIFOX and achieved regulatory approval from the FDA, produced a median OS of 9.2 months. The ACCENT mOS of 11.1 months is therefore meaningfully above both of these comparators on a headline basis, though direct cross-trial comparisons must be treated with appropriate caution given differences in patient populations, enrollment criteria, and staging. What is particularly notable is that the NAPOLI 3 trial delivered a median OS of 11.1 months for NALIRIFOX, which is identical to the figure recorded in ACCENT, and which the FDA found sufficient to support approval. Amplia Therapeutics has not indicated it will seek approval based on Phase 1b/2a data alone, but the parallel to an approved regimen gives ACCENT a credible survival benchmark heading into any potential Phase 3 design conversation.

Equally significant is what was not observed. Narmafotinib continues to be well tolerated, with the adverse effect profile of the narmafotinib-chemotherapy combination described as broadly comparable to chemotherapy alone. For oncology drugs seeking to move from Phase 2 to Phase 3 development, a clean safety signal is as commercially important as efficacy, because it reduces the argument that any efficacy gain is purchased at an unacceptable tolerability cost. In pancreatic cancer, where patients typically present with advanced disease and deteriorating performance status, a therapy that improves outcomes without layering on additional toxicity has a meaningful advantage in both clinical adoption and regulatory review.

What does the independent central read methodology mean for the credibility of the ACCENT trial results?

The upgrade from one to five complete responses came from an expert central reading of scans conducted by an independent contracted laboratory, rather than from the site investigators who had been reporting responses throughout the trial. This distinction matters. Regulatory agencies and institutional investors apply different levels of confidence to data generated by trial site investigators versus data validated through centralised, blinded, standardised re-assessment. Site investigators operate under real-world clinical conditions and are not always optimally calibrated for the precise application of RECIST 1.1 criteria. Central read laboratories exist specifically to apply these criteria with consistency, and their determinations carry substantially greater weight in regulatory submissions and partner due diligence processes.

Amplia Therapeutics had planned from the outset to conduct an independent central read as the trial approached completion, with that milestone expected in Q3 2026. The fact that the central read has already been initiated and has generated significant positive revisions to the response data is an important credibility signal for the ACCENT dataset as a whole. The company is now positioned to present data at the AACR annual meeting in April 2026 that carries the methodological weight of an independent assessment, which is qualitatively different from presenting investigator-assessed data. That distinction is likely to influence how partnership discussions, licensing conversations, or equity funding rounds are framed in the period following the conference.

What are the strategic and commercial implications of Amplia’s AACR presentation for the narmafotinib program?

The AACR annual meeting is one of the most significant venues in global oncology for Phase 2 clinical data. Presentations at AACR attract attendance from business development teams at major pharmaceutical and biotechnology companies, academic key opinion leaders who influence clinical practice, and specialist healthcare investors who fund early-stage oncology development. For a clinical-stage ASX company with a market capitalisation below A$100 million, securing a presentation slot at AACR with data of this profile is a material commercial catalyst. The selection implies that the AACR scientific programme committee found the ACCENT data sufficiently novel to warrant formal presentation, which itself functions as independent scientific endorsement.

Pancreatic cancer represents one of the largest unmet needs in oncology and, correspondingly, one of the most actively pursued commercial opportunities for large pharmaceutical developers. Focal adhesion kinase inhibition has attracted increasing interest as a mechanism that acts on the tumour microenvironment rather than directly on cancer cell proliferation, which gives narmafotinib a differentiated mechanism rationale compared to standard cytotoxics or KRAS-targeted approaches that dominate current commercial interest in pancreatic cancer. Amplia Therapeutics also has the AMPLICITY trial underway, evaluating narmafotinib in combination with FOLFIRINOX, a second standard-of-care chemotherapy regimen for this disease. That parallel trial expands the addressable patient population and provides additional data that could support a broader commercial narrative for the asset.

How are ATX shares trading and does the market valuation reflect the clinical progress in the ACCENT trial?

Amplia Therapeutics shares were trading at approximately A$0.163 around the time of the announcement, placing the company’s market capitalisation at roughly A$83 million. The stock carries a 52-week range of A$0.049 to A$0.425, meaning that at current prices it remains well below its 12-month high despite sitting approximately 75% above its 52-week low. The solo analyst covering the stock had a price target of A$0.42, implying significant upside from current levels before this announcement. These market data points reflect a stock that has already recovered substantially from a low base but has not yet re-rated to the valuation implied by its prior high or the available analyst estimate.

The gap between current trading levels and the 52-week high may partly reflect investor scepticism about the commercial path from Phase 1b/2a data to a partnered Phase 3 development program, a transition that requires capital, a partner, and regulatory agreement on trial design. Clinical-stage companies with promising Phase 2 data in difficult indications frequently trade below their theoretical value until a partnership, licensing deal, or funded Phase 3 announcement removes uncertainty from the commercialisation pathway. The AACR presentation in April 2026, combined with the upgraded dataset from independent central reading, creates a visible near-term catalyst window. Whether that translates into sustained re-rating will depend in part on what additional data the company can extract from further analysis of the ACCENT dataset before and during the conference.

What execution risks and development pathway uncertainties remain for narmafotinib in pancreatic cancer?

The ACCENT trial is a single-arm open-label study, which means it lacks a concurrent control arm. While the historical comparators from MPACT and NAPOLI 3 provide a useful efficacy benchmark, regulators and large pharmaceutical development partners typically require randomised controlled trial evidence before committing to late-stage development or commercial acquisition. The strength of the complete response and overall survival data from ACCENT improves the probability that a credible Phase 3 design discussion can be initiated, but it does not eliminate the need for a substantially larger and more complex trial to achieve regulatory approval. For a company of Amplia Therapeutics’ size, funding and managing a Phase 3 pancreatic cancer trial independently would represent an exceptionally challenging capital allocation and operational undertaking.

The commercial pathway therefore depends on attracting a development partner with Phase 3 execution capability and resources, or on securing non-dilutive funding through mechanisms such as orphan drug designation, grants, or government-backed clinical trial support. Amplia Therapeutics’ existing IND approval in the United States for the AMPLICITY trial provides a US clinical infrastructure that may assist in attracting North American partnership interest, given that the US oncology market is the primary commercial prize for any approved pancreatic cancer therapy. The trial’s conclusion is expected in Q3 2026, at which point the complete dataset will be available for full analysis and external review.

Key takeaways: What the ACCENT trial results mean for Amplia Therapeutics, competitors, and the pancreatic cancer sector

• Amplia Therapeutics has confirmed five complete responses in the ACCENT trial, producing a 7.8% CR rate that is approximately 25 to 39 times higher than the 0.2% to 0.3% CR rates observed in the MPACT and NAPOLI 3 reference trials, representing a genuinely unprecedented data point in first-line advanced pancreatic cancer.
• The independent central read methodology adds significant regulatory and commercial credibility to the ACCENT dataset, distinguishing it from investigator-reported data and making it more directly usable in partnership due diligence or regulatory pre-submission discussions.
• A median overall survival of 11.1 months places narmafotinib on par with NALIRIFOX from the NAPOLI 3 trial, the most recently approved chemotherapy regimen for this indication, providing a meaningful precedent for the survival threshold the FDA has already found acceptable for regulatory approval.
• The objective response rate of 35.9% is now essentially equivalent to NAPOLI 3’s 36.2%, reinforcing the competitive positioning of the narmafotinib-gemcitabine-Abraxane combination relative to both existing standard-of-care regimens.
• Narmafotinib’s tolerability profile, described as comparable to chemotherapy alone with no additional toxicity burden, is a commercially important attribute that strengthens the product’s potential for combination with multiple chemotherapy backbones across different patient subgroups.
• Selection for presentation at the AACR annual meeting in April 2026 in San Diego provides Amplia Therapeutics with direct access to pharmaceutical business development teams, oncology key opinion leaders, and specialist investors at the most commercially relevant oncology forum of the year.
• The AMPLICITY trial, evaluating narmafotinib with FOLFIRINOX, expands the program’s addressable patient population and provides a second clinical dataset that could underpin a broader commercial narrative for the asset beyond the ACCENT results.
• At approximately A$0.163 per share and a market capitalisation near A$83 million, ATX remains well below its 52-week high of A$0.425, suggesting the market has not yet fully re-rated the stock to reflect the clinical progress visible in the independent central read data.
• The primary commercial risk remains the transition from a single-arm Phase 1b/2a study to a randomised Phase 3 program, which requires a development partner or significant capital, and that uncertainty will continue to act as a ceiling on the stock’s valuation absent a formal partnership announcement.
• Focal adhesion kinase inhibition in the tumour microenvironment represents a mechanistic approach distinct from both standard cytotoxic chemotherapy and the KRAS-targeted therapies attracting the most capital in current pancreatic cancer drug development, which gives narmafotinib a differentiated commercial argument in partnership discussions.